MTOR and neuroendocrine neoplasm: Biotherapy with somatostatin analogues, the mTOR inhibitor everolimus, the VEGF inhibitor sunitinib, and 177Lu-DOTATATE radionuclide therapy has emerged as evidence-based treatment of advanced G1/G2 neuroendocrine tumors prolonging PFS and/or OS.